Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances. Grafa is not liable for any loss caused, whether due ...

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances. Grafa is not liable for any loss caused, whether due ...

· Janus Henderson acquires Antares and Fairview to form a $66.6 billion Australian funds business. · The corporate announcement triggered strategic portfolio expansions without immediate share price ...

· Equinix appointed former Vocus executive Jarrod Nink as its new managing director for Australia. · Following the executive announcement, Equinix shares traded higher at US$1,084.24. · The leadership ...

Tesla reported second-quarter revenue of $28.2 billion, up 26%, but adjusted EPS of $0.33 missed analyst expectations. Tesla shares were down 1.3% at $374.17 in the latest after-hours trading ...

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances. Grafa is not liable for any loss caused, whether due ...

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances. Grafa is not liable for any loss caused, whether due ...

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances. Grafa is not liable for any loss caused, whether due ...

Proxy adviser CGI Glass Lewis warns Macquarie will face intense shareholder questioning at its upcoming annual general meeting. The scrutiny centres on the appointment of KPMG as auditor amidst a data ...

Keel appointed former Digital Realty executive Ganesh Aiyer as president, sending its shares up 10% in early trading. The appointment supports Keel's expansion into AI infrastructure following its ...

TG Therapeutics (NASDAQ:TGTX) initiated a Phase 2 trial of BRIUMVI in treatment-resistant schizophrenia. The study enrolls about 60 adults and evaluates BRIUMVI alongside standard antipsychotic ...

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances. Grafa is not liable for any loss caused, whether due ...